# Phase 3 Study of BK1310 in Healthy Infants

> **NCT02992925** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 370 (actual)

## Conditions studied

- Immunization; Infection

## Interventions

- **BIOLOGICAL:** DPT-IPV-Hib-High（Combined Vaccine）
- **BIOLOGICAL:** DPT-IPV-Hib-Low（Combined Vaccine）
- **BIOLOGICAL:** Hib vaccine
- **BIOLOGICAL:** DPT-IPV

## Key facts

- **NCT ID:** NCT02992925
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-12
- **Final completion:** 2018-11
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02992925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02992925, "Phase 3 Study of BK1310 in Healthy Infants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02992925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*